{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:17:56Z","timestamp":1780409876715,"version":"3.54.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["CA175691"],"award-info":[{"award-number":["CA175691"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00101","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T06:05:51Z","timestamp":1581401151000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Preclinical Models of Malignant Mesothelioma"],"prefix":"10.3389","volume":"10","author":[{"given":"Joseph R.","family":"Testa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Berns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.12688\/f1000research.15512.2","article-title":"Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort [version 3]","volume":"7","author":"Amin","year":"2018","journal-title":"F1000Res."},{"key":"B2","first-page":"5547","article-title":"p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma","volume":"54","author":"Cheng","year":"1994","journal-title":"Cancer Res."},{"key":"B3","first-page":"511","article-title":"Codeletion of p15 and p16 in primary malignant mesothelioma","volume":"11","author":"Xio","year":"1995","journal-title":"Oncogene."},{"key":"B4","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc Natl Acad Sci USA."},{"key":"B5","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1158\/0008-5472.CAN-05-2312","article-title":"A mouse model recapitulating molecular features of human mesothelioma","volume":"65","author":"Altomare","year":"2005","journal-title":"Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J Thorac Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl Lung Cancer Res."},{"key":"B15","first-page":"5410","article-title":"Genetic alterations of the p53 gene are a feature of malignant mesothelioma","volume":"51","author":"Cote","year":"1991","journal-title":"Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","article-title":"PTEN expression is a strong predictor of survival in mesothelioma patients","volume":"33","author":"Opitz","year":"2008","journal-title":"Eur J Cardiothorac Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s13277-012-0615-9","article-title":"PTEN protein expression in malignant pleural mesothelioma","volume":"34","author":"Agarwal","year":"2013","journal-title":"Tumour Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1016\/j.ejca.2010.06.130","article-title":"Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma","volume":"46","author":"Perrone","year":"2010","journal-title":"Eur J Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/1947601910375273","article-title":"A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma","volume":"1","author":"Menges","year":"2010","journal-title":"Genes Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e105919","DOI":"10.1371\/journal.pone.0105919","article-title":"MET and PI3K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma","volume":"9","author":"Kanteti","year":"2014","journal-title":"PLoS ONE."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2016.03.001","article-title":"Analysis of expression of PTEN\/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"96","author":"Cedres","year":"2016","journal-title":"Lung Cancer."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene."},{"key":"B24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition","volume":"24","author":"Quispel-Janssen","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e30224","DOI":"10.7554\/eLife.30224","article-title":"Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells","volume":"7","author":"Kolluri","year":"2018","journal-title":"eLife."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/ijc.25202","article-title":"Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer","volume":"126","author":"Delage","year":"2010","journal-title":"Int J Cancer."},{"key":"B28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cncr.10923","article-title":"The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions","volume":"99","author":"Illei","year":"2003","journal-title":"Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science."},{"key":"B33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","article-title":"The emerging roles of YAP and TAZ in cancer","volume":"15","author":"Moroishi","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"B34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-3-319-53560-9_8","volume-title":"Asbestos and Mesothelioma","author":"Cheung","year":"2017"},{"key":"B35","first-page":"1524","article-title":"SV40 induces mesothelioma in hamsters","volume":"142","author":"Cicala","year":"1993","journal-title":"Am J Pathol."},{"key":"B36","first-page":"448","article-title":"Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats","volume":"24","author":"Craighead","year":"1987","journal-title":"Am J Path."},{"key":"B37","first-page":"6455","article-title":"Chromosomal translocations with specific breakpoints in asbestos-induced rat mesotheliomas","volume":"48","author":"Libbus","year":"1988","journal-title":"Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2307\/3433511","article-title":"Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers","volume":"105","author":"Marsella","year":"1997","journal-title":"Environ Health Perspect."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/carcin\/21.5.1023","article-title":"mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats","volume":"21","author":"Sandhu","year":"2000","journal-title":"Carcinogenesis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/bjc.1969.70","article-title":"Mesotheliomas in rats following inoculation with asbestos","volume":"23","author":"Wagner","year":"1969","journal-title":"Br J Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/thx.33.2.181","article-title":"An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain\/Urgup in Anatolia","volume":"33","author":"Baris","year":"1978","journal-title":"Thorax."},{"key":"B42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2068","article-title":"A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes","volume":"7","author":"Carbone","year":"2007","journal-title":"Nat Rev Cancer."},{"key":"B43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/bjc.1985.108","article-title":"Erionite exposure and mesotheliomas in rats","volume":"51","author":"Wagner","year":"1985","journal-title":"Br J Cancer."},{"key":"B44","first-page":"617","article-title":"The long term fibrogenic effects of chrysotile and crocidolite asbestos dust injected into the pleural cavity of experimental animals","volume":"51","author":"Davis","year":"1970","journal-title":"Br J Exp Pathol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/0013-9351(74)90050-4","article-title":"Inhalation carcinogenesis from various forms of asbestos","volume":"8","author":"Reeves","year":"1974","journal-title":"Environ Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0013-9351(84)90136-1","article-title":"Malignant mesothelioma induced by asbestos and zeolite in the mouse peritoneal cavity","volume":"35","author":"Suzuki","year":"1984","journal-title":"Environ Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/toxsci\/68.2.331","article-title":"Accelerated progression of asbestos-induced mesotheliomas in heterozygous p53(+\/\u2013) mice","volume":"68","author":"Vaslet","year":"2002","journal-title":"Toxicol Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1038\/sj.onc.1206593","article-title":"Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours","volume":"22","author":"Fleury-Feith","year":"2003","journal-title":"Oncogene."},{"key":"B49","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1158\/0008-5472.CAN-05-4668","article-title":"A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent","volume":"66","author":"Robinson","year":"2006","journal-title":"Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1073\/pnas.0808816106","article-title":"Activated TNF-alpha\/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice","volume":"106","author":"Altomare","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","article-title":"Losses of both products of the Cdkn2a\/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis","volume":"6","author":"Altomare","year":"2011","journal-title":"PLoS ONE."},{"key":"B52","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/icb.2012.46","article-title":"NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma","volume":"90","author":"Chow","year":"2012","journal-title":"Immunol Cell Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","article-title":"Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations","volume":"76","author":"Kadariya","year":"2016","journal-title":"Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/1940-6207.CAPR-15-0347","article-title":"Inflammation-related IL1\u03b2\/IL1R signaling promotes the development of asbestos-induced malignant mesothelioma","volume":"9","author":"Kadariya","year":"2016","journal-title":"Cancer Prev Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-13-2062","article-title":"Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis","volume":"74","author":"Menges","year":"2014","journal-title":"Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/mc.2940140105","article-title":"Effects of genetic background on tumorigenesis in p53-deficient mice","volume":"14","author":"Donehower","year":"1995","journal-title":"Mol Carcinog."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J Natl Cancer Inst."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene."},{"key":"B60","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2010.08.015","article-title":"MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma","volume":"47","author":"Robinson","year":"2011","journal-title":"Eur J Cancer."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(04)17102-X","article-title":"Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids","volume":"364","author":"Lopez-Rios","year":"2004","journal-title":"Lancet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1023\/A:1014321729038","article-title":"Reappraisal of the strong association between simian virus 40 and human malignant mesothelioma of the pleura (Belgium)","volume":"13","author":"H\u00fcbner","year":"2002","journal-title":"Cancer Causes Control."},{"key":"B63","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1186\/s12885-015-1953-y","article-title":"Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma","volume":"15","author":"Robinson","year":"2015","journal-title":"BMC Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","article-title":"A conditional mouse model for malignant mesothelioma","volume":"12","author":"Jongsma","year":"2008","journal-title":"Cancer Cell."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/nar\/25.9.1766","article-title":"Cre-mediated somatic site-specific recombination in mice","volume":"25","author":"Akagi","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science."},{"key":"B68","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","article-title":"Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models","volume":"79","author":"Kukuyan","year":"2019","journal-title":"Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"8952","DOI":"10.1002\/jcp.26830","article-title":"Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas","volume":"233","author":"Sementino","year":"2018","journal-title":"J Cell Physiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.4161\/cc.9.9.11545","article-title":"Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA","volume":"9","author":"Zhao","year":"2010","journal-title":"Cell Cycle."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-16-0844","article-title":"Patient-derived xenograft establishment from human malignant pleural mesothelioma","volume":"23","author":"Wu","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fgene.2018.00232","article-title":"Pre-clinical models for malignant mesothelioma research: from chemical-induced to patient-derived cancer xenografts","volume":"9","author":"Nabavi","year":"2018","journal-title":"Front Genet."},{"key":"B74","doi-asserted-by":"publisher","first-page":"E9626","DOI":"10.1073\/pnas.1705301114","article-title":"Humanized mouse model supports development, function, and tissue residency of human natural killer cells","volume":"114","author":"Herndler-Brandstetter","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B75","doi-asserted-by":"publisher","first-page":"14.21.1","DOI":"10.1002\/0471141755.ph1421s54","article-title":"Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden","volume":"54","author":"Servais","year":"2011","journal-title":"Curr Protoc Pharmacol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T06:05:56Z","timestamp":1581401156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":75,"alternative-id":["10.3389\/fonc.2020.00101"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00101","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"article-number":"101"}}